Patent-pending real-time quantitative PCR testing platform was acquired by Access Genetics from Sensible Diagnostics.
EDEN PRAIRIE, Minn., Oct. 22, 2024 /PRNewswire/ — Access Genetics dba OralDNA® Labs is proud to announce that it has acquired all assets of Sensible Diagnostics Inc., San Dimas, CA. With this acquisition, OralDNA intends to commercialize a new standard in point-of-care molecular diagnostics, offering speed and affordability. The goal is central lab quality test results from saliva or swabs in 10 minutes or less.
“We are proud to add Sensible Diagnostics’ state-of-the-art platform to our capabilities, enhancing our ability to provide real-time, actionable results to clinicians and their patients. This acquisition underscores our commitment to innovation in healthcare diagnostics,” said George Hoedeman, CEO at OralDNA Labs.
With a fast, 4-channel system and convenient microfluidic test cartridges, OralDNA Labs aims to improve the speed and accuracy of chairside diagnostics. Initial development has focused on the oral microbiome with a plan to support dentists in the diagnosis and treatment of periodontal disease and possibly related oral systemic illnesses. The platform and assays under development have not received FDA clearance and are not currently for sale.
About Access Genetics and OralDNA® Labs
Access Genetics offers cutting-edge DNA testing at its CLIA-certified and CAP-accredited national reference laboratories. OralDNA® Labs is an innovator in salivary diagnostics with a comprehensive menu of infectious and human genetic markers. With over 24 years of expertise and a commitment to exceptional customer service, Access Genetics and OralDNA® stand out as leaders in the industry.
For media inquiries, please contact:
Amanda Seaton
855-672-5362
384741@email4pr.com
SOURCE OralDNA Labs
Evidence-informed course equips non-professionals to respond to mental health crises with practical, scalable skills Project…
-- Femasys continues to expand access and market share for its first-line infertility treatment option,…
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve…
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or…
Vanessa Tolosa joins as Senior Vice President of Research and Development; Vivek Pinto as Director…
BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI),…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="196px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="300px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="12px" width="12px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="1000px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
